Skip to main content
SpringerLink
Log in
Book cover

Molecular Basis of Thyroid Cancer pp 357–367Cite as

Pathobiology of Antineoplastic Therapy in Undifferentiated Thyroid Cancer

  • Chapter

Part of the Cancer Treatment and Research book series (CTAR,volume 122)

Keywords

  • Thyroid Cancer
  • Thyroid Carcinoma
  • Differentiate Thyroid Carcinoma
  • Multidrug Resistance Protein
  • Anaplastic Thyroid Carcinoma

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (Canada)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (Canada)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ain KB 2000 Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14:615–29.

    CrossRef  CAS  PubMed  Google Scholar 

  2. Ain KB 1999 Anaplastic thyroid carcinoma: a therapeutic challenge. Sem Surg Oncol 16:64.

    CAS  Google Scholar 

  3. Ain KB 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715–726.

    CAS  PubMed  Google Scholar 

  4. Alison M 2002 The cancer handbook. Nature Pub. Group; Distributed in the U.S. by Grove’s Dictionaries, London, New York.

    Google Scholar 

  5. Souhami RL 2002 Oxford textbook of oncology, 2nd ed. Oxford University Press, Oxford; New York.

    Google Scholar 

  6. Orlandi F, Caraci P, Berruti A, et al. 1994 Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5:763–765.

    CAS  PubMed  Google Scholar 

  7. Tallroth E, Wallin G, Lundell G, Löwhagen T, Einhorn J 1987 Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 60:1428–1431.

    CAS  PubMed  Google Scholar 

  8. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C 1990 Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76:480–3.

    CAS  PubMed  Google Scholar 

  9. Nederman T 1984 Effects of vinblastine and 5-fluorouracil on human glioma and thyroid cancer cell monolayers and spheroids. Cancer Res 44:254–8.

    CAS  PubMed  Google Scholar 

  10. Kim R, Tanabe K, Uchida Y, Emi M, Toge T 2003 Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. Int J Mol Med 11:799–804.

    CAS  PubMed  Google Scholar 

  11. Misaki T, Iwata M, Lida Y, Kasagi K, Konishi J 2002 Chemo-radionuclide therapy for thyroid cancer: initial experimental study with cultured cells. Ann Nucl Med 16:403–8.

    CAS  PubMed  Google Scholar 

  12. Ringel MD, Greenberg M, Chen X, et al. 2000 Cytotoxic activity of 2’,2’-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells. Thyroid 10:865–9.

    CAS  PubMed  Google Scholar 

  13. Voigt W, Bulankin A, Muller T, et al. 2000 Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 6:2087–93.

    CAS  PubMed  Google Scholar 

  14. Kotchetkov R, Groschel B, Gmeiner WH, et al. 2000 Antineoplastic activity of a novel multi-meric gemcitabine-monophosphate prodrug against thyroid cancer cells in vitro. Anticancer Res 20:2915–22.

    CAS  PubMed  Google Scholar 

  15. Kotchetkov R, Krivtchik AA, Cinatl J, Kornhuber B, Cinatl J, Jr. 1999 Selective cytotoxic activity of a novel ribonucleoside diphosphate reductase inhibitor MDL-101, 731 against thyroid cancer in vitro. Folia Biol (Praha) 45:185–91.

    CAS  Google Scholar 

  16. Jereb B, Stjernswärd J, Löwhagen T 1975 Anaplastic giant-cell carcinoma of the thyroid: a study of treatment and prognosis. Cancer 35:1293–1295.

    CAS  PubMed  Google Scholar 

  17. Hoskin PJ, Harmer C 1987 Chemotherapy for thyroid cancer. Radiother Oncol 10:187–94.

    CAS  PubMed  Google Scholar 

  18. Palyi I, Peter I, Daubner D, Vincze B, Lorincz I 1993 Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Arch B Cell Pathol Incl Mol Pathol 63:263–9.

    CAS  PubMed  Google Scholar 

  19. Yoshida A, Fukazawa M, Aiyoshi Y, Soeda S, Ito K 1990 The biological characteristics and chemosensitivity of anaplastic thyroid carcinoma transplanted into nude mice. Jpn J Surg 20:690–5.

    CAS  PubMed  Google Scholar 

  20. Asakawa H, Kobayashi T, Komoike Y, et al. 1997 Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 17:2757–2762.

    CAS  PubMed  Google Scholar 

  21. Tallroth E, Wallin G, Lundell G, Lowhagen T, Einhorn J 1987 Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 60:1428–31.

    CAS  PubMed  Google Scholar 

  22. Andersson T, Biorklund A, Landberg T, Akerman M, Aspegren K, Ingemansson S 1977 Combined therapy for undifferentiated giant and spindle cell carcinoma of the thyroid. Acta Otolaryngol 83: 372–7.

    CAS  PubMed  Google Scholar 

  23. Bernhardt B 1981 Follicular thyroid carcinoma: response to chemotherapy. Am J Med Sci 282:45–6.

    CAS  PubMed  Google Scholar 

  24. De Besi P, Busnardo B, Toso S, et al. 1991 Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14:475–80.

    PubMed  Google Scholar 

  25. Farid NR 2001 P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Invest 24:536–45.

    CAS  PubMed  Google Scholar 

  26. van der Zee AG, Hollema HH, de Bruijn HW, et al. 1995 Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 58:165–78.

    PubMed  Google Scholar 

  27. Fineman LS, Hamilton TA, de Gortari A, Bonney P 1998 Cisplatin chemotherapy for treatment of thyroid carcinoma in dogs: 13 cases. J Am Anim Hosp Assoc 34:109–12.

    CAS  PubMed  Google Scholar 

  28. Ekman ET, Lundell G, Tennvall J, Wallin G 1990 Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin NA 23:523–527.

    CAS  Google Scholar 

  29. Scherubl H, Raue F, Ziegler R 1990 Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116:21–3.

    CAS  Google Scholar 

  30. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D 1991 Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67:564–6.

    CAS  PubMed  Google Scholar 

  31. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–60.

    CAS  PubMed  Google Scholar 

  32. Santini F, Bottici V, Elisei R, et al. 2002 Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 87:4160–5.

    CrossRef  CAS  PubMed  Google Scholar 

  33. Ahuja S, Ernst H 1987 Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10:303–310.

    CAS  PubMed  Google Scholar 

  34. Poster DS, Bruno S, Penta J, Pina K, Catane R 1981 Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin Trials 4:301–7.

    CAS  PubMed  Google Scholar 

  35. Gottlieb JA, Hill CS, Jr 1974 Chemotherapy of thyroid cancer with Adriamycin. Experience with 30 patients. N Engl J Med 290:193–7.

    CAS  PubMed  Google Scholar 

  36. Kim JH, Leeper RD 1983 Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination adriamycin and radiation therapy: A new approach. Cancer 52:954–57.

    CAS  PubMed  Google Scholar 

  37. Kim JH, Leeper RD 1987 Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60:2372–75.

    CAS  PubMed  Google Scholar 

  38. Shade RJ, Pisters KM, Huber MH, et al. 1998 Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs 16:237–43.

    CrossRef  CAS  PubMed  Google Scholar 

  39. Williams SD, Birch R, Einhorn LH 1986 Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70:405–7.

    CAS  PubMed  Google Scholar 

  40. Benjamin RS, Keating MJ, Swenerton KD, Legha S, McCredie KB 1979 Clinical studies with rubida-zone. Cancer Treat Rep 63:925–9.

    CAS  PubMed  Google Scholar 

  41. Di Bartolomeo M, Bajetta E, Bochicchio AM, et al. 1995 A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol 6:77–9.

    PubMed  Google Scholar 

  42. Schlumberger M, Parmentier C 1989 Phase II evaluation of mitoxantrone in advanced non anaplastic thyroid cancer. Bull Cancer 76:403–406.

    CAS  PubMed  Google Scholar 

  43. Kober F, Heiss A, Keminger K, Depisch D 1990 [Chemotherapy of highly malignant thyroid tumors]. Wien Klin Wochenschr 102:274–6.

    CAS  PubMed  Google Scholar 

  44. Osawa Y, Yoshida A, Asaga T, Kawahara S, Yanoma S 1996 [In vitro chemosensitivity test for seven undifferentiated thyroid carcinoma cell lines using MTT assay]. Gan To Kagaku Ryoho 23:471–6.

    CAS  PubMed  Google Scholar 

  45. Lee A, LiVolsi VA, Baloch ZW 2000 Expression of DNA topoisomerase IIalpha in thyroid neoplasia. Mod Pathol 13:396–400.

    CrossRef  CAS  PubMed  Google Scholar 

  46. Leaf AN, Wolf BC Kirkwood JM, Haselow RE 2000 Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). Med Oncol 17:47–51.

    CAS  PubMed  Google Scholar 

  47. Ain KB, Ishizawar RC, Taylor KD Suramin inhibits growth of differentiated and anaplastic human thyroid carcinomas in monolayer and spheroid cultures with disparate effects in vivo. 76th Annual Meeting of the Endocrine Society, Anaheim, CA, 1994.

    Google Scholar 

  48. Harada T, Nishikawa Y, Suzuki T, Ito K, Baba S 1971 Bleomycin treatment for cancer of the thyroid. Am J Surg 122:53–7.

    CrossRef  CAS  PubMed  Google Scholar 

  49. Hayat M 1977 Ou en est la chimiotherapie des cancers de lo thyroïde? (Status of chemotherapy for thyroid carcinomas). Ann Radiol 20:807–9.

    Google Scholar 

  50. Benker G, Hackenberg K Hoff HG, et al. 1977 [Combined doxorubicin and bleomycin treatment of metastasising thyroid carcinoma: results in 21 patients (author’s transl)]. Dtsch Med Wochenschr 102:1908–13.

    CAS  PubMed  Google Scholar 

  51. Busnardo B, Daniele O, Pelizzo MR, et al. 2000 A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Invest 23:755–61.

    CAS  PubMed  Google Scholar 

  52. Spanos GA, Wol KD, Desner MR, et al. 1982 Preoperative chemotherapy for giant cell carcinoma of the thyroid. Cancer 50:2252–6.

    CAS  PubMed  Google Scholar 

  53. Bukowski RM, Brown L, Weick JK, Groppe CW, Purvis J 1983 Combination chemotherapy of metastatic thyroid cancer: phase II study. Am J Clin Oncol (CCT) 6:579–81.

    CAS  Google Scholar 

  54. Jordan MA, Wilson L 1998 Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opm Cell Biol 10:123–30.

    CAS  Google Scholar 

  55. Ain KB, Tofiq S, Taylor KD 1996 Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650–3.

    CrossRef  CAS  PubMed  Google Scholar 

  56. Ain KB, Egorin MJ, DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–94.

    CAS  PubMed  Google Scholar 

  57. Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A 2000 Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60:650–6.

    CAS  PubMed  Google Scholar 

  58. Xu G, Pan J, Martin C Yeung SC 2001 Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86:1769–77.

    CrossRef  CAS  PubMed  Google Scholar 

  59. Pietras K, Stumm M, Hubert M, et al. 2003 STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 9:3779–87.

    CAS  PubMed  Google Scholar 

  60. Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY 2001 Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor. Oncogene 20:3845–56.

    CrossRef  CAS  PubMed  Google Scholar 

  61. Pietras K, Rubin K, Sjoblom T, et al. 2002 Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476–84.

    CAS  PubMed  Google Scholar 

  62. Sokal M, Harmer CL 1978 Chemotherapy for anaplastic carcinoma of the thyroid. Clin Oncol 4:3–10.

    CAS  PubMed  Google Scholar 

  63. Alexieva-Figusch J, Van Gilse HA, Treurniet RE 1977 Chemotherapy in carcinoma of the thyroid: retrospective and prospective, Ann Radiol 20:810–13.

    CAS  PubMed  Google Scholar 

  64. Dowlati A, Robertson K, Cooney M, et al. 2002 A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408–16.

    CAS  PubMed  Google Scholar 

  65. Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB 2002 Combretastatin a4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 12:1063–70.

    CrossRef  CAS  PubMed  Google Scholar 

  66. Griggs J, Metcalfe JC, Hesketh R 2001 Targeting tumor vasculature: the development of combretastatin A4. The Lancet Oncology 2:82–87.

    CrossRef  CAS  PubMed  Google Scholar 

  67. Gottesman MM, Pastan I 1993 Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427.

    CrossRef  CAS  PubMed  Google Scholar 

  68. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I 1987 Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265–9.

    CAS  PubMed  Google Scholar 

  69. Chin KV, Ueda K Pastan I, Gottesman MM 1992 Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459–62.

    CAS  PubMed  Google Scholar 

  70. Pauli-Magnus C, von Richter O, Burk O et al. 2000 Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 293:376–82.

    CAS  PubMed  Google Scholar 

  71. Borst P, Evers R, Kool M, Wijnholds J 2000 A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–302.

    CrossRef  CAS  PubMed  Google Scholar 

  72. Kool M, de Haas M, Scheffer GL, et al. 1997 Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537–47.

    CAS  PubMed  Google Scholar 

  73. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SP, Deeley RG, Gerlach JH 1999 Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 5:673–80.

    CAS  PubMed  Google Scholar 

  74. Zelcer N, Reid G, Wielinga P, et al. 2003 Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 371:361–7.

    CrossRef  CAS  PubMed  Google Scholar 

  75. Wijnholds J, Mol CA, van Deemter L, et al. 2000 Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97:7476–81.

    CrossRef  CAS  PubMed  Google Scholar 

  76. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ 2000 Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12:550–6.

    CrossRef  CAS  PubMed  Google Scholar 

  77. Sugawara I, Akiyama S, Scheper RJ, Itoyama S 1997 Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 112:23–31.

    CrossRef  CAS  PubMed  Google Scholar 

  78. Sekiguchi M, Shiroko Y, Arai T, et al. 2001 Biological characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines. Biomed Pharmacother 55:466–74.

    CrossRef  CAS  PubMed  Google Scholar 

  79. Sugawara I, Masunaga A, Itoyama S, Sumizawa T, Akiyama S, Yamashita T 1995 Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. Cancer Lett 95:135–8.

    CrossRef  CAS  PubMed  Google Scholar 

  80. Yamashita T, Watanabe M, Onodera M, et al. 1994 Multidrug resistance gene and P-glycoprotein expression in anaplastic carcinoma of the thyroid. Cancer Detect Prev 18:407–13.

    CAS  PubMed  Google Scholar 

  81. Satake S, Sugawara I, Watanabe M, Takami H 1997 Lack of a point mutation of human DNA topoi-somerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Letters 116:33–39.

    CrossRef  CAS  PubMed  Google Scholar 

  82. Loe DW, Deeley RG, Cole SPC 1996 Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A:945–957.

    CAS  PubMed  Google Scholar 

  83. Niitsu Y, Takahashi Y, Ban N, et al. 1998 A proof of glutathione S-transferase-pi-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell. Chem Biol Interact 111–112:325–32.

    PubMed  Google Scholar 

  84. Dincer Y, Akcay T, Celebi N, Uslu I, Ozmen O, Hatemi H 2002 Glutathione S-transferase and O6-methylguanine DNA methyl transferase activities in patients with thyroid papillary carcinoma. Cancer Invest 20:965–71.

    CAS  PubMed  Google Scholar 

  85. Shahedian B, Shi Y, Zou M, Farid NR 2001 Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab 72:155–63.

    CrossRef  CAS  PubMed  Google Scholar 

  86. Blagosklonny MV, Giannakakou P, Wojtowicz M, et al. 1998 Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 83:2516–22.

    CrossRef  CAS  PubMed  Google Scholar 

  87. Nagayama Y, Yokoi H, Takeda K., et al. 2000 Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85:4081–6.

    CrossRef  CAS  PubMed  Google Scholar 

  88. Ceraline J, Deplanque G, Noel F, Natarajan-Ame S, Bergerat JP, Klein-Soyer C 2003 Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function. Cancer Chemother Pharmacol 51:91–5.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thyroid Oncology Program, Division of Hematology & Oncology, Department of Internal Medicine, University of Kentucky, Lexington, KY, 40536

    Kenneth B. Ain M.D.

  2. Thyroid Cancer Research Laboratory, Veterans Affairs Medical Center, Lexington, KY, 40511

    Kenneth B. Ain M.D.

Authors
  1. Kenneth B. Ain M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Osancor Biotech, Inc., Watford, WD17 3BY, Herts, UK

    Nadir R. Farid

Rights and permissions

Reprints and Permissions

Copyright information

© 2005 Springer Science + Business Media, Inc.

About this chapter

Cite this chapter

Ain, K.B. (2005). Pathobiology of Antineoplastic Therapy in Undifferentiated Thyroid Cancer. In: Farid, N.R. (eds) Molecular Basis of Thyroid Cancer. Cancer Treatment and Research, vol 122. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8107-3_20

Download citation

  • DOI: https://doi.org/10.1007/1-4020-8107-3_20

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-8106-4

  • Online ISBN: 978-1-4020-8107-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

search

Navigation